Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Lymphoma 17Leukemia, Myeloid, Acute 16Breast Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Multiple Myeloma 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 11Carcinoma, Non-Small-Cell Lung 11Lymphoma, Mantle-Cell 10Leukemia 10Lymphoma, Follicular 9Hodgkin Disease 9Myelodysplastic Syndromes 8Recurrence 7Neuroblastoma 7Neoplasm Metastasis 7Leukemia, Lymphocytic, Chronic, B-Cell 7Brain Neoplasms 7Neoplasms, Plasma Cell 6Lymphoma, B-Cell, Marginal Zone 6Lung Neoplasms 6Glioblastoma 6Prostatic Neoplasms 5Pancreatic Neoplasms 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, T-Cell 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, B-Cell 5Immunoblastic Lymphadenopathy 5Burkitt Lymphoma 5

Interventions

Arsenic Trioxide 21Tretinoin 20Cytarabine 12Cyclophosphamide 11Busulfan 10Methotrexate 9Idarubicin 9Filgrastim 8fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 6Tacrolimus 5Gemtuzumab 5Etoposide 5Radiotherapy 4Clofarabine 4Antilymphocyte Serum 4Topotecan 3Mycophenolic Acid 3Mitoxantrone 3Mercaptopurine 3Daunorubicin 3venetoclax 2lintuzumab 2Whole-Body Irradiation 2Thiotepa 2Sorafenib 2Granulocyte Colony-Stimulating Factor 2Cyclosporins 2Cyclosporine 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Promyelocytic, Acute × Vorinostat × Clear all
NCT00875745 2014-09-18

Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Indiana University

Phase 1 Completed
15 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡